Company profile
Polaryx Therapeutics, Inc.
NASDAQ:PLYXBiotechnology: Pharmaceutical Preparations
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT07740512 | phase2 | not_yet_recruiting | 2026-12-01 | 2028-12-31 | Polaryx Therapeutics, Inc. | Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of PLX-200 in Pediatric Patients (Master Protocol) |
| NCT04637282 | phase3 | withdrawn | 2026-11-01 | 2026-12-31 | Polaryx Therapeutics, Inc. | Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3 |
FDA applications (0)
No records yet.